OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press11810.17650/1818-8346-2014-9-3-6-15HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯInterim results of the Ph-negative acute lymphoblastic leukemia treatment in adult patients (results of Russian research group of ALL treatment (RALL))Промежуточные результаты по лечению острых Ph-негативных лимфобластных лейкозов у взрослых больных (итоги Российской исследовательской группы по лечению острых лимфобластных лейкозов (RALL))ParovichnikovaE. N.ПаровичниковаЕ. Н.
Russian Federation
elenap@blood.ruTroitskayaV. V.ТроицкаяВ. В.
Russian Federation
SokolovA. N.СоколовА. Н.
Russian Federation
AkhmerzaevaZ. Kh.АхмерзаеваЗ. Х.
Russian Federation
KuzminaL. A.КузьминаЛ. А.
Russian Federation
MendeleevaL. P.МенделееваЛ. П.
Russian Federation
KlyasovaG. A.КлясоваГ. А.
Russian Federation
KravchenkoS. K.КравченкоС. К.
Russian Federation
GribanovaYe. O.ГрибановаЕ. О.
Russian Federation
BondarenkoS. N.БондаренкоС. Н.
Russian Federation
BaranovaO. Yu.БарановаО. Ю.
Russian Federation
KaporskayaT. S.КапорскаяТ. С.
Russian Federation
RyltsovaT. V.РыльцоваТ. В.
Russian Federation
NizamutdinovaA. S.НизамутдиноваА. С.
Russian Federation
ZagoskinaT. P.ЗагоскинаТ. П.
Russian Federation
ZininaYe. Ye.ЗининаЕ. Е.
Russian Federation
SamoylovaO. S.СамойловаО. С.
Russian Federation
KlimovichA. V.КлимовичА. В.
Russian Federation
KaryakinaYe. A.КарякинаЕ. А.
Russian Federation
Yelufer’evaA. S.ЕлуферьеваА. С.
Russian Federation
GavrilovaL. V.ГавриловаЛ. В.
Russian Federation
KonstantinovaT. S.КонстантиноваТ. С.
Russian Federation
ToropovaI. Yu.ТороповаИ. Ю.
Russian Federation
PristupaA. S.ПриступаА. С.
Russian Federation
VopilinaN. A.ВопилинаН. А.
Russian Federation
TikunovaT. S.ТикуноваТ. С.
Russian Federation
SkamorinaO. P.СкаморинаО. П.
Russian Federation
KaplanovK. D.КаплановК. Д.
Russian Federation
ObukhovaT. N.ОбуховаТ. Н.
Russian Federation
GaltsevaI. V.ГальцеваИ. В.
Russian Federation
RusinovM. A.РусиновМ. А.
Russian Federation
KulikovS. M.КуликовС. М.
Russian Federation
SavchenkoV. G.СавченкоВ. Г.
Russian Federation
Hematologic Scientific Center, Ministry of Health of Russia, MoscowФГБУ «Гематологический научный центр» Минздрава России, МоскваRaisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia2Научно-исследовательский институт детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова» Минздрава РоссииN.N. Blokhin Russian Cancer Research Center, MoscowФГБНУ «Российский онкологический научный центр им. Н. Н. Блохина», МоскваIrkutsk Regional HospitalГБУЗ «Иркутская ордена “Знак почета” областная клиническая больница»Tula Regional HospitalГУЗ ТО «Тульская областная клиническая больница»Municipal Alexander Hospital, St.-PetersburgСПб ГУЗ «Городская Александровская больница», Санкт-ПетербургKirov Research Institute of Hematology and Blood Transfusion, Federal Medical and Biological AgencyФГБУН «Кировский научно-исследовательский институт гематологии и переливания крови» ФМБА РоссииSurgut Regional HospitalБУ ХМАО-Югры «Сургутская окружная клиническая больница»N.A. Semashko Regional Clinical Hospital, N. NovgorodГБУЗ НО «Нижегородская областная клиническая больница им. Н. А. Семашко», Нижний НовгородCity Clinical Hospital ‡‚ 31, St..PetersburgСПб ГУЗ «Городская клиническая больница № 31», Санкт-ПетербургCity Hospital № 15, St.‑PetersburgСПб ГУЗ «Городская больница № 15», Санкт-ПетербургM.I. Kalinin Regional Clinical Hospital, SamaraГБУЗ «Самарская областная клиническая больница им. М. И. Калинина»Mordovian Republican Clinical Hospital, SaranskГБУЗ РМ «Мордовская республиканская клиническая больница», СаранскRegional Hematology Center, Sverdlovsk Regional Clinical Hospital № 1, YekaterinburgОбластной гематологический центр ГБУЗ СО «Свердловская областная клиническая больница № 1», ЕкатеринбургRegional Clinical Hospital, YaroslavlГБУЗ ЯО «Областная клиническая больница», ЯрославльRegional Clinical Hospital, RyazanГБУ РО «Областная клиническая больница», РязаньV.D. Babenko Regional Clinical Hospital, TambovГБУЗ «Тамбовская областная клиническая больница им. В. Д. Бабенко»St. Ioasafa Belgorod Regional HospitalОГБУЗ «Белгородская областная клиническая больница Святителя Иоасафа»Central Clinical Military Hospital, Federal Security Service of Russia, MoscowФГУП «Центральный клинический военный госпиталь Федеральной службы безопасности РФ», МоскваRegional Clinical Oncology Dispensary № 1, VolgogradГБУЗ «Волгоградский областной клинический онкологический диспансер № 1»301020149361530012015300120152014https://oncohematology.abvpress.ru/ongm/article/view/118

An interim analysis of long-term treatment results for 202 patients with acute lymphoblastic leukemia (ALL), aged 15–60 years, received therapy according protocol ALL-2009 was shown. The basic principle of ALL-2009 was non-aggressive, but continued cytostatic exposure, as well as the reproducibility in a regional hematology centers. Long-term treatment results of ALL-2009 are 2 times higher than the previously obtained in adult ALL patients within the Russian clinical multicenter studies of adult ALL. The 5‑year overall survival of patients younger than 30 years was 73.6 %, relapse-free survival (RFS) – 71.5 %, compared with 52.7 % and 61.8 % in patients aged 30 years and older, respectively. In patients with B-precursor ALL with normal karyotype of blast cells significantly higher 5‑year RFS (82.1 %) compared to patients with abnormal karyotype (58.8 %) was registered. For T-ALL cytogenetic characteristics of blast cells had no prognostic significance. For patients with T-ALL important to perform autologous stem cell transplantation as a later consolidation, as this significantly reducerelapse rate (from 33 to 0 %).

acute lymphoblastic leukemia in adultschromosomal abnormalitiesautologous stem cell transplantationострый лимфобластный лейкоз у взрослыххромосомные аномалиитрансплантация аутологичных стволовых клеток1. Goldstone A. H., Richards S. M., Lazarus H. M. et al. In adults with standardrisk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation / maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII / ECOG E2993). Blood 2008;111(4):1827–33.Goldstone A. H., Richards S. M., Lazarus H. M. et al. In adults with standardrisk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation / maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII / ECOG E2993). Blood 2008;111(4):1827–33.2. Arnold R., Terwey T. H., Vuong G. L. et al. Allogeneic stem cell transplantation in adults with high risk acute lymphoblastic leukemia (ALL) In first remission (CR1): promising, but strongly influenced by ALL subtypes. Blood 2013;122(21):abstr. 3409.Arnold R., Terwey T. H., Vuong G. L. et al. Allogeneic stem cell transplantation in adults with high risk acute lymphoblastic leukemia (ALL) In first remission (CR1): promising, but strongly influenced by ALL subtypes. Blood 2013;122(21):abstr. 3409.3. Recommendations of the European working group for adult ALL. Editor in chief N. Goekbuget. UNI-MED Verlag AG, Kurfurstenallee 130, D-28211 Bremen, Germany.Recommendations of the European working group for adult ALL. Editor in chief N. Goekbuget. UNI-MED Verlag AG, Kurfurstenallee 130, D-28211 Bremen, Germany.4. Huang J., Zou D.-H., Li Z.-J. et al. An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: report from a single center of China. Bone Marrow Transplant 2012;47:1087–94.Huang J., Zou D.-H., Li Z.-J. et al. An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: report from a single center of China. Bone Marrow Transplant 2012;47:1087–94.5. Nachmann S., Sather H. N., Buckley J. D. et al. Young adults 16–21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 1993;71: 3377–84.Nachmann S., Sather H. N., Buckley J. D. et al. Young adults 16–21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 1993;71: 3377–84.6. Shiffer C. A. Differences in outcome in adolescence and young adults with ALL: a consequence of better regimens? Better doctors? Both? JCO 2003;21:760.Shiffer C. A. Differences in outcome in adolescence and young adults with ALL: a consequence of better regimens? Better doctors? Both? JCO 2003;21:760.7. Ram R., Wolach O., Vidal L. et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatricinspired regimens: systematic review and meta-analysis. Am J Hematol 2012;87(5):472–8.Ram R., Wolach O., Vidal L. et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatricinspired regimens: systematic review and meta-analysis. Am J Hematol 2012;87(5):472–8.8. Stock W., La M., Sanford B. et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Leukemia Group B studies. Blood 2008;112:1646–54.Stock W., La M., Sanford B. et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Leukemia Group B studies. Blood 2008;112:1646–54.9. Boissel N., Auclerc M. F., Lheritier V. et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of French FRALLE-93 and LALA-94 trials. JCO 2003;21:774–80.Boissel N., Auclerc M. F., Lheritier V. et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of French FRALLE-93 and LALA-94 trials. JCO 2003;21:774–80.10. de Bont J. M., Holt B., Dekker A. W. et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric versus adult protocols in the Netherlands. Leukemia 2004;18:2032–5.de Bont J. M., Holt B., Dekker A. W. et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric versus adult protocols in the Netherlands. Leukemia 2004;18:2032–5.11. Ramanujachar R., Richards S., Hann I. et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII / E2993) trials. Pediatr Blood Cancer 2007;48:254–6.Ramanujachar R., Richards S., Hann I. et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII / E2993) trials. Pediatr Blood Cancer 2007;48:254–6.12. Testi A., Valsecchi M., Conter V. et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood 2004;104(11): abstr. 539a.Testi A., Valsecchi M., Conter V. et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood 2004;104(11): abstr. 539a.13. Hallbook H., Gustafsson G., Smedmyr B. et al. Treatment outcome in young adults and children > 10 years of age with acute lymphoblastic leukemia in weden: comparison between a pediatric protocol and an adult protocol. Cancer 2006;107:1551–61.Hallbook H., Gustafsson G., Smedmyr B. et al. Treatment outcome in young adults and children > 10 years of age with acute lymphoblastic leukemia in weden: comparison between a pediatric protocol and an adult protocol. Cancer 2006;107:1551–61.14. Usvasalo A., Raty R., Knuutila S. et al. Acute lympnoblastic leukemias in adolescents and yaoung adaults in Finland. Haematol 2008;93(8):1161–8.Usvasalo A., Raty R., Knuutila S. et al. Acute lympnoblastic leukemias in adolescents and yaoung adaults in Finland. Haematol 2008;93(8):1161–8.15. DeAngelo D.J., Stevenson K. E., Dahlberg S. E. et al. Long-term outcome of a pediatric-inspired regimen used for adults ages 18 to 50 with newly diagnosed acute lymphoblastic leukemia. Leukemia 2014 Jul 31. doi: 10.1038 / leu.2014.229. [Epub ahead of print].DeAngelo D.J., Stevenson K. E., Dahlberg S. E. et al. Long-term outcome of a pediatric-inspired regimen used for adults ages 18 to 50 with newly diagnosed acute lymphoblastic leukemia. Leukemia 2014 Jul 31. doi: 10.1038 / leu.2014.229. [Epub ahead of print].16. Савченко В. Г., Паровичникова Е. Н., Исаев В. Г. и др. Лечение острых лимфобластных лейкозов взрослых как нерешенная проблема. Тер архив 2001;(7):6–15.Савченко В. Г., Паровичникова Е. Н., Исаев В. Г. и др. Лечение острых лимфобластных лейкозов взрослых как нерешенная проблема. Тер архив 2001;(7):6–15.17. Karachunskiy A., Herold R., von Stackelberg A. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22(6):1144–53.Karachunskiy A., Herold R., von Stackelberg A. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22(6):1144–53.18. Laporte J. P., Yeshurun M., Fouillard L. et al. A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant. Leukemia 2004;18(10):1717–21.Laporte J. P., Yeshurun M., Fouillard L. et al. A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant. Leukemia 2004;18(10):1717–21.19. Программное лечение заболеваний системы крови. Под ред. В. Г. Савченко. М.: Практика, 2012. С. 289–342.Программное лечение заболеваний системы крови. Под ред. В. Г. Савченко. М.: Практика, 2012. С. 289–342.20. Паровичникова Е. Н., Клясова Г. А., Исаев В. Г. и др. Первые итоги терапии Ph-негативных острых лимфобластных лейкозов взрослых по протоколу Научно- исследовательской группы гематологических центров России ОЛЛ-2009. Тер архив 2011;(7):11–7.Паровичникова Е. Н., Клясова Г. А., Исаев В. Г. и др. Первые итоги терапии Ph-негативных острых лимфобластных лейкозов взрослых по протоколу Научно- исследовательской группы гематологических центров России ОЛЛ-2009. Тер архив 2011;(7):11–7.21. Паровичникова Е. Н., Савченко В. Г., Давидян Ю. Р. и др. Итоги лечения острых лимфобластных лейкозов взрослых по протоколу ОЛЛ-2005 как основа для новых исследований. Тер архив 2009; 7):8–15.Паровичникова Е. Н., Савченко В. Г., Давидян Ю. Р. и др. Итоги лечения острых лимфобластных лейкозов взрослых по протоколу ОЛЛ-2005 как основа для новых исследований. Тер архив 2009; 7):8–15.22. Gomez-Sequi I., Cervera J., Such E. et al. Prognostic value of cytogenetics in adult patients with hiladelphia negative acute lymphoblastic leukemia. Ann Hematol 2012;91:19–25.Gomez-Sequi I., Cervera J., Such E. et al. Prognostic value of cytogenetics in adult patients with hiladelphia negative acute lymphoblastic leukemia. Ann Hematol 2012;91:19–25.